We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Adam Feldman

Adam Feldman MD, MPH

Director of Research for the Department of Urology at Massachusetts General Hospital; Director of the Combined Harvard Fellowship Program in Urologic Oncology, Boston, MA
Dr. Adam S. Feldman is the Director of Research for the Department of Urology at Massachusetts General Hospital and Director of the Combined Harvard Fellowship Program in Urologic Oncology. He completed his residency in urology in 2006 and subsequently completed his fellowship in urologic oncology in June 2008. Dr. Feldman focuses his clinical practice in the treatment of prostate cancer, kidney cancer and other genitourinary malignancies. He focuses his research interests on translational and clinical research in kidney and prostate cancers. He has received a Prostate Cancer Foundation Young Investigator Award for his work in novel biomarkers in prostate cancer and has been awarded a Physician Research Training Award by the Department of Defense. He is a co-PI on a Department of Defense Synergistic Idea Development Award on the development of conditionally reprogrammed cells in prostate cancer and is a co-investigator on an National Institutes of Health RO1 on metabolomic imaging in prostate cancer. In addition to his translational research work in genitourinary cancer biomarkers, he has worked to develop clinical databases in active surveillance in prostate cancer, use of imaging and fusion biopsy in prostate cancer, surgical and ablative treatments for renal cell carcinoma, and renal mass biopsy.